383 related articles for article (PubMed ID: 32929364)
1. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.
Wang L; Lang GT; Xue MZ; Yang L; Chen L; Yao L; Li XG; Wang P; Hu X; Shao ZM
Theranostics; 2020; 10(23):10531-10547. PubMed ID: 32929364
[No Abstract] [Full Text] [Related]
2. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
3. The microRNA target site landscape is a novel molecular feature associating alternative polyadenylation with immune evasion activity in breast cancer.
Kim S; Bai Y; Fan Z; Diergaarde B; Tseng GC; Park HJ
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32844230
[TBL] [Abstract][Full Text] [Related]
4. Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation.
Miles WO; Lembo A; Volorio A; Brachtel E; Tian B; Sgroi D; Provero P; Dyson N
Cancer Res; 2016 Dec; 76(24):7231-7241. PubMed ID: 27758885
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
6. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of Alternative Polyadenylation in Human Cancer.
Xiang Y; Ye Y; Lou Y; Yang Y; Cai C; Zhang Z; Mills T; Chen NY; Kim Y; Muge Ozguc F; Diao L; Karmouty-Quintana H; Xia Y; Kellems RE; Chen Z; Blackburn MR; Yoo SH; Shyu AB; Mills GB; Han L
J Natl Cancer Inst; 2018 Apr; 110(4):379-389. PubMed ID: 29106591
[TBL] [Abstract][Full Text] [Related]
8. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.
Mou E; Wang H
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31399501
[TBL] [Abstract][Full Text] [Related]
9. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
10. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
11. Suppression of cleavage factor Im 25 promotes the proliferation of lung cancer cells through alternative polyadenylation.
Huang J; Weng T; Ko J; Chen NY; Xiang Y; Volcik K; Han L; Blackburn MR; Lu X
Biochem Biophys Res Commun; 2018 Sep; 503(2):856-862. PubMed ID: 29928883
[TBL] [Abstract][Full Text] [Related]
12. 3'UTR shortening and EGF signaling: implications for breast cancer.
Akman HB; Oyken M; Tuncer T; Can T; Erson-Bensan AE
Hum Mol Genet; 2015 Dec; 24(24):6910-20. PubMed ID: 26395459
[TBL] [Abstract][Full Text] [Related]
13. Alternative polyadenylation of single cells delineates cell types and serves as a prognostic marker in early stage breast cancer.
Kim N; Chung W; Eum HH; Lee HO; Park WY
PLoS One; 2019; 14(5):e0217196. PubMed ID: 31100099
[TBL] [Abstract][Full Text] [Related]
14. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
15. A Cancer-Specific Ubiquitin Ligase Drives mRNA Alternative Polyadenylation by Ubiquitinating the mRNA 3' End Processing Complex.
Yang SW; Li L; Connelly JP; Porter SN; Kodali K; Gan H; Park JM; Tacer KF; Tillman H; Peng J; Pruett-Miller SM; Li W; Potts PR
Mol Cell; 2020 Mar; 77(6):1206-1221.e7. PubMed ID: 31980388
[TBL] [Abstract][Full Text] [Related]
16. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract][Full Text] [Related]
17. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.
Wang Z; Wang X
J Cell Physiol; 2020 Mar; 235(3):2825-2835. PubMed ID: 31541468
[TBL] [Abstract][Full Text] [Related]
18. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
